And so, another working week will soon draw to a close. Not a moment, too soon, yes? This is, you may recall, our treasured signal for daydreaming about weekend plans. Under the circumstances, you may not be surprised to hear our agenda is quite modest. We plan to catch up on our reading, take a constitutional or two, and train the official mascot to do household chores. And what about you? This is a fine time to do some spring cleaning. Conversely, you could partake in the great outdoors (but try to avoid crowds). Or perhaps reach out to folks who feel isolated. Well, whatever you do, have a grand time. But be safe, and wear a mask. Enjoy, and see you soon. …

The Trump administration mishandled the initial distribution of remedesivir, the experimental Gilead Sciences (GILD) Covid-19 medicine, delaying treatment to some critically ill patients, The Washington Post reports. The first tranche of 607,000 vials was distributed in early May — in some cases to the wrong hospitals, to hospitals with no intensive care units and therefore no eligible patients, and to facilities without needed refrigeration for storage, meaning some had to be returned to the government.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy